Blood Cancer UK and Cancer Research UK recognise the need and impact of artificial intelligence approaches developed by Professor Daniel Royston and Professor Jens Rittscher for early detection and assessment of these blood cancers.
In a pan-cancer analysis spanning 24 different cancer types, researchers shed light on the relationship between SETD2, DNA methylation and cancer development.
The National Institute for Health and Care Research (NIHR) has announced a major investment in its Policy Research Units (PRUs). Researchers in the Nuffield Department of Primary Care Health Sciences at Oxford will play a key role in a new Unit focusing on the early detection of cancer.
Oxford researchers have been given a \u00a31 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.
David Hunter, Richard Doll Professor of Epidemiology and Medicine at Oxford Population Health and OxCODE Associate Director, has been appointed as a Companion of the Order of Australia in the Australian King\u2019s Birthday Honours List.
An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.
A team of researchers from the University of Oxford and the University of Nottingham have developed \u2018CanPredict\u2019, a new tool able to identify those most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and lives.
Researchers and clinicians in Oxford have begun an evaluation of artificial intelligence (AI) software that could help pathologists diagnose prostate cancer.
Cancer Research UK and the National Institute for Health and Care Research are investing over \u00a33 million across the next five years into The University of Oxford\u2019s Experimental Cancer Medicine Centre (ECMC). The investment will enable Oxford to expand its portfolio of precision prevention and early detection cancer trials.
IBD-associated colorectal cancers were found to occur in younger patients and have worse outcomes. Researchers call for urgent improvement of early detection methods to provide more risk-based and personalised care.
Dr Bornschein will join the Simmons Group (MRC Human Immunology Unit) for a project developing strategies to identify patients at high risk of gastritis/gastric cancer.
Organised by the NIHR Oxford Biomedical Research Centre, Professor Mark Middleton and patient representative Sue Duncombe discuss how cancer blood tests are being assessed and how they may change how cancer is diagnosed in the NHS.
This initiative, announced by the NHS England Chief Executive, is part of the drive to diagnose cancers earlier in the NHS by \u201cfast-tracking\u201d community-based diagnostic testing.
Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research suggests. Weight loss and increasing blood glucose levels are early indicators of pancreatic cancer and could lead to a more timely diagnosis, helping to improve survival rates.
The NIHR Oxford Biomedical Research Centre (BRC), a partnership between the University of Oxford and Oxford University Hospitals (OUH) NHS Foundation Trust, will receive \u00a386.6m over the next five years to fund 15 research themes.
![\"\"](\"https://www.oxcode.ox.ac.uk/news/double-funding-success-to-improve-detection-and-risk-classification-of-myeloproliferative-neoplasms-mpns/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n